These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36112472)

  • 1. Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the CAPTURE study.
    Davis TME; Colman PG; Hespe C; Heywood SE; d'Emden M
    Intern Med J; 2023 Oct; 53(10):1796-1805. PubMed ID: 36112472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy.
    Russo GT; Corigliano G; Arturi F; Cavallo MG; Bette C; Mannucci E
    Nutr Metab Cardiovasc Dis; 2022 May; 32(5):1195-1201. PubMed ID: 35260306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.
    Mosenzon O; Alguwaihes A; Leon JLA; Bayram F; Darmon P; Davis TME; Dieuzeide G; Eriksen KT; Hong T; Kaltoft MS; Lengyel C; Rhee NA; Russo GT; Shirabe S; Urbancova K; Vencio S;
    Cardiovasc Diabetol; 2021 Jul; 20(1):154. PubMed ID: 34315481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
    Østergaard HB; Humphreys V; Hengeveld EM; Honoré JB; Mach F; Visseren FLJ; Westerink J; Yadav G; Mosenzon O;
    Diabetes Obes Metab; 2023 Feb; 25(2):435-443. PubMed ID: 36199242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.
    Morton JI; Marquina C; Shaw JE; Liew D; Polkinghorne KR; Ademi Z; Magliano DJ
    Diabetologia; 2023 Apr; 66(4):642-656. PubMed ID: 36404375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.
    Eliasson B; Ekelund J; Holmberg CN; Wolden ML; Matthiessen KS; James S
    Eur J Prev Cardiol; 2023 May; 30(7):546-551. PubMed ID: 36567502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
    Nair R; Mody R; Yu M; Cowburn S; Konig M; Prewitt T
    Diabetes Ther; 2022 Dec; 13(11-12):1921-1932. PubMed ID: 36131064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
    JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.
    Davies MJ; Drexel H; Jornayvaz FR; Pataky Z; Seferović PM; Wanner C
    Cardiovasc Diabetol; 2022 Aug; 21(1):144. PubMed ID: 35927730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020.
    Sherrill CH; Hwang AY
    Ann Pharmacother; 2024 Mar; 58(3):248-254. PubMed ID: 37323006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
    Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
    Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
    Ann Intern Med; 2021 Nov; 174(11):1528-1541. PubMed ID: 34570599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.